Bubble or no bubble, this is the best stock for AI exposure: analyst
Investing.com - UBS raised its price target on Cytokinetics (NASDAQ:CYTK) to $61.00 from $41.00 on Monday, while maintaining a Neutral rating on the stock.
The price target adjustment comes as Cytokinetics shares have surged 125% over the past six months, initially climbing after the ESC Conference and continuing to outperform alongside other cardiology stocks and the broader XBI index.
UBS analyst Ashwani Verma noted that despite the significant price increase, the firm sees "balanced risk/reward" for the stock heading into its year-end approval decision.
The investment bank expressed pessimism regarding the company’s non-obstructive hypertrophic cardiomyopathy (nHCM) study outcome expected in the second quarter of 2026, as well as concerns about the 2026 product launch dynamics.
UBS believes Cytokinetics will "struggle" with its 2026 launch, contributing to the firm’s decision to maintain its Neutral stance despite the substantially higher price target.
In other recent news, Cytokinetics reported its Q3 2025 earnings, revealing a significant revenue miss. The company posted revenue of $1.93 million, falling short of the forecasted $6.05 million, resulting in a 68.1% revenue miss. Despite this, there was a notable EPS surprise, with an actual EPS of -$2.55 compared to the forecast of -$1.57. Additionally, RBC Capital has raised its price target for Cytokinetics to $87 from $82, maintaining an Outperform rating. This adjustment reflects updated modeling assumptions for the anticipated 2026 launch of aficamten. Furthermore, Cytokinetics appointed Jeffrey J. Hessekiel as Executive Vice President and Chief Legal Officer. Hessekiel brings extensive legal experience from his previous role at Exelixis, Inc. These developments highlight recent strategic and financial activities within the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.